These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
211 related items for PubMed ID: 1878583
1. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D, Riehm H. Blood; 1991 Sep 01; 78(5):1166-72. PubMed ID: 1878583 [Abstract] [Full Text] [Related]
2. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. BFM (Berlin-Frankfurt-Münster) Relapse Study Group. Bührer C, Hartmann R, Fengler R, Schober S, Arlt I, Loewke M, Henze G. Blood; 1994 Jun 15; 83(12):3468-72. PubMed ID: 8204875 [Abstract] [Full Text] [Related]
3. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Dopfer R, Henze G, Bender-Götze C, Ebell W, Ehninger G, Friedrich W, Gadner H, Klingebiel T, Peters C, Riehm H. Blood; 1991 Nov 15; 78(10):2780-4. PubMed ID: 1824271 [Abstract] [Full Text] [Related]
8. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Reiter A, Schrappe M, Ludwig WD, Lampert F, Harbott J, Henze G, Niemeyer CM, Gadner H, Müller-Weihrich S, Ritter J. Blood; 1992 Nov 15; 80(10):2471-8. PubMed ID: 1421370 [Abstract] [Full Text] [Related]
9. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, Ebell W, Escherich G, Schrappe M, Klingebiel T, Fengler R, Henze G, von Stackelberg A. J Clin Oncol; 2010 May 10; 28(14):2339-47. PubMed ID: 20385996 [Abstract] [Full Text] [Related]
10. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials. Schrappe M, Reiter A, Henze G, Niemeyer C, Bode U, Kühl J, Gadner H, Havers W, Plüss H, Kornhuber B, Zintl F, Ritter J, Urban C, Niethammer D, Riehm H. Klin Padiatr; 1998 May 10; 210(4):192-9. PubMed ID: 9743952 [Abstract] [Full Text] [Related]
11. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi A, Miniero R, Di Tullio MT, Lo Nigro L, Pession A, Rondelli R, Messina C, Santoro N, Mori PG, De Rossi G, Tamaro P, Silvestri D, Biondi A, Basso G, Masera G. Haematologica; 1998 Sep 10; 83(9):791-9. PubMed ID: 9825576 [Abstract] [Full Text] [Related]
16. Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation. BFM Relapse Study Group. Borgmann A, Hartmann R, Schmid H, Klingebiel T, Ebell W, Göbel U, Peters C, Gadner H, Henze G. Bone Marrow Transplant; 1995 Apr 10; 15(4):515-21. PubMed ID: 7655375 [Abstract] [Full Text] [Related]
17. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A, Lutz P, Mechinaud F, Robert A, Boutard P, Marguerite G, Ferster A, Plouvier E, Rialland X, Behard C, Plantaz D, Dresse MF, Philippet P, Norton L, Thyss A, Dastugue N, Waterkeyn C, Vilmer E, Otten J, Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer. J Clin Oncol; 2001 Apr 01; 19(7):1935-42. PubMed ID: 11283125 [Abstract] [Full Text] [Related]
18. High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. von Stackelberg A, Hartmann R, Bührer C, Fengler R, Janka-Schaub G, Reiter A, Mann G, Schmiegelow K, Ratei R, Klingebiel T, Ritter J, Henze G, ALL-REZ BFM Study Group. Blood; 2008 Mar 01; 111(5):2573-80. PubMed ID: 18089849 [Abstract] [Full Text] [Related]
19. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Kamps WA, Bökkerink JP, Hählen K, Hermans J, Riehm H, Gadner H, Schrappe M, Slater R, van den Berg-de Ruiter E, Smets LA, de Vaan GA, Weening RS, van Weerden JF, van Wering ER, den der Does-van den Berg A. Blood; 1999 Aug 15; 94(4):1226-36. PubMed ID: 10438710 [Abstract] [Full Text] [Related]
20. Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia. Dördelmann M, Reiter A, Zimmermann M, Fengler R, Henze G, Riehm H, Schrappe M. J Pediatr Hematol Oncol; 1998 Aug 15; 20(5):444-50. PubMed ID: 9787317 [Abstract] [Full Text] [Related] Page: [Next] [New Search]